SSI Mantra: Robotic Surgery: India Achieves First Dual-Console on Beating Heart
India has reached a historic milestone with the successful completion of a dual‑console beating‑heart TECAB operation using a domestically developed robotic platform. The procedure was performed by a team of cardiac surgeons at a leading tertiary centre, marking the first time this technique has been carried out in the country. The operation combined minimally invasive coronary bypass with a beating‑heart approach, eliminating the need for cardiopulmonary bypass.
SSI Mantra dual console breakthroughThe dual‑console configuration allowed two surgeons to operate simultaneously, each controlling separate instrument arms while a third console managed visualisation and navigation. Five robotic arms were employed to perform the intricate coronary anastomoses on a beating heart, a setup previously demonstrated only in experimental settings abroad. The system, identified as the SSI Mantra platform, is entirely manufactured in India and offers a home‑grown alternative to imported devices.
Robotic‑assisted cardiac interventions are gaining traction worldwide, promising reduced trauma, shorter hospital stays and faster recovery compared with conventional open‑heart surgery. The beating‑heart TECAB technique further minimizes physiological stress by avoiding cardiopulmonary bypass. Recent global developments, such as the FDA clearance of Medtronic’s Hugo system for general surgery, illustrate the expanding role of robotic platforms across specialties. India’s achievement places the nation among a select group of countries capable of delivering fully endoscopic coronary bypass procedures.
The introduction of the domestically produced dual‑console system could broaden access to cutting‑edge cardiac care across Indian states, reducing reliance on costly imported equipment. Local hospitals may adopt the technology more rapidly, creating training opportunities for surgeons and fostering a supply chain that supports Indian manufacturers. Observers anticipate further applications of the SSI Mantra platform in valve repair and complex congenital cases, while clinical evaluations will generate long‑term safety and efficacy data to guide regulatory and reimbursement decisions.
Also Read:
- Deep Tech India: Sovereign funds aim to double AI capital, but how will startups benefit?
- GTA 6: Launch tomorrow in India with pre‑load steps, but what storage space is needed?
- Applied Compute: Palo Alto Acquires AI Startup for $4.5 Billion
For more news..